TIL
“Harnessing the Power of Tumor-Infiltrating Lymphocytes”
As part of our product pipeline, our company is advancing TIL therapy in collaboration with leading hospitals. By leveraging our translational research platform and clinical partnerships, we are developing innovative TIL therapies to address the challenges of solid tumors and provide new treatment options for cancer patients.
Product Overview
TIL therapy is an adoptive cell therapy that isolates naturally occurring T cells from a patient’s tumor tissue, expands them ex vivo, then reinfuses them to strengthen the body’s ability to fight cancer. TILs recognize a broad range of tumor-associated antigens, making them particularly effective against heterogeneous tumors.
Clear and Reliable Source: With direct collaborations with hospitals, tumor tissue samples are traceable and well-documented, ensuring product quality and compliance.
Broad & Precise Targeting: TILs recognize multiple tumor-associated antigens, offering both breadth and precision in elimination heterogeneous tumor cells.
Personalized Therapy: Derived from each patient’s own tumor, TIL therapy is inherently individualized, maximizing clinical relevance and therapeutic potential.
Advantages
Clinical Applications
TIL therapy has shown encouraging results in solid tumors, particularly melanoma, cervical cancer, and other hard-to-treat cancers. Our company is advancing TIL research on hepatobiliary and pancreatic cancers, urological cancers, cervical cancer, ovarian cancer, liver cancer, and non-small cell lung cancer.
Established collaboration with Shenzhen University General Hospital and the Third Affiliated Hospital of Sun Yat-sen University to advance TIL therapy in hepatobiliary and pancreatic cancers.
Partnered with the First Affiliated Hospital of Xiamen University to explore TIL applications in urological cancers.